VOLUMETRIC MAPPING OF BREAST CANCER BIOMARKERS USING H-S MR SPECTRO IMAGING

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在这个项目中，我们将开发一个超高速并行MRSI技术的基础上质子回波平面光谱成像（PEPSI）和并行MRI（SENSE/GRAPPA）的人乳房。我们将评估单次激发PEPSI与超分辨率SENSE重建（SURE-SENSE）的可行性，SURE-SENSE是一种新型的并行MRI，特别适用于低分辨率MRSI。该方法将使用新型16通道乳腺RF阵列线圈来实现，与传统RF线圈设计相比，该线圈提供显著更高的灵敏度，并且能够实现更快的并行成像加速。我们在人类乳房中的初步结果证明了在短时间内进行高质量2D和3D PEPSI的可行性。我们的目标是：1）开发3 T乳腺超高速并行3D MRSI; 2）使用3 T超高速3D MRSI作为乳腺癌检测和治疗反应评估的工具。如果成功，这项技术将被用作乳腺癌诊断和治疗监测的工具。长期目标是利用MRSI作为接受乳腺癌全身治疗（即化疗，内分泌治疗）的女性治疗失败的早期预测因子，并为高危患者制定改进的筛查方案。在接受新辅助治疗的患者中，准确早期识别治疗失败或成功可以节省大量时间和资源，并最大限度地减少患者风险和暴露于无效药物的潜在副作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In this project we will develop an ultra high-speed parallel MRSI technique for the human breast based on Proton Echo Planar Spectroscopic Imaging (PEPSI) and parallel MRI (SENSE/GRAPPA). We will assess the feasibility of single-shot PEPSI with Superresolution SENSE reconstruction (SURE-SENSE), a novel form of parallel MRI, which is particularly suitable for low resolution MRSI. This methodology will be implemented using a novel 16-channel breast RF array coil that provides significantly higher sensitivity and enables much faster parallel imaging acceleration as compared to conventional RF coil designs. Our preliminary results in the human breast demonstrate the feasibility of high quality 2D and 3D PEPSI in short measurement time. Our aims are to 1) Develop ultra high-speed parallel 3D MRSI for the breast at 3 T; and 2) Use ultra high-speed 3D MRSI at 3 T as a tool for breast cancer detection and treatment response assessment. If successful, the developed technique will be used as a tool for breast cancer diagnosis and treatment monitoring. The long-term goals are to utilize MRSI as an early predictor of treatment failure in women undergoing systemic therapy (i.e. chemotherapy, endocrine therapy) for breast cancer and to develop an improved screening protocol for high-risk patients. In patients undergoing neoadjuvant therapies, accurate early identification of treatment failure or success could save significant time and resources, and minimize patient risk and exposure to potential side effects from medications that are not efficacious.